Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The MOVE-study: Morning Versus Evening Administration of 500 mcg Roflumilast Once Daily for 6 Weeks in Patients With Asthma

NCT00163475 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00163475
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00163475 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The MOVE-study: Morning Versus Evening Administration of 500 mcg Roflumilast Once Daily for 6 Weeks in Patients With Asthma
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2004
Completion date
August 31, 2005
Enrollment
511
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

asthma